Physician profile
Douglas E Severance
NPI 1639289838
$15,347.75
in general payments reported to CMS, 2019-2025
59 companies · $1,640 in 2025
The $1,640 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,106 · 2020: $2,916 · 2021: $2,170 · 2022: $1,943 · 2023: $2,350 · 2024: $2,222 · 2025: $1,640.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,181 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,180.56 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,075.44 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,311.00 | 2019-2025 | |
| Abbvie INC. | $1,271.06 | 2019-2025 | Vraylar, Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $955.94 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $882.47 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $849.56 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Allergan, INC. | $808.31 | 2019-2021 | |
| Amgen INC. | $743.38 | 2019-2025 | Repatha, Otezla, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $529.05 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $526.67 | 2019-2022 | |
| Indivior INC. | $453.89 | 2019-2025 | Sublocade |
| Orexo US, INC. | $360.53 | 2019-2020 | |
| Amarin Pharma, INC. | $264.14 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $226.65 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $197.81 | 2021-2025 |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $191.51 | 2019-2024 | |
| Glaxosmithkline, LLC. | $169.48 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $166.21 | 2019-2024 | Veozah |
| Biohaven Pharmaceuticals, INC. | $164.29 | 2021 | |
| Mdd US Operations, LLC | $141.05 | 2019 | |
| Braeburn INC. | $140.06 | 2023-2024 | Brixadi |
| Merck Sharp & Dohme LLC | $133.87 | 2019-2021 | |
| Exact Sciences Corporation | $130.55 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $122.07 | 2023-2025 | Gemtesa |
| Janssen Pharmaceuticals, INC | $121.06 | 2021-2023 | Xarelto |
| Abbott Laboratories | $102.34 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Kowa Pharmaceuticals America, INC. | $97.11 | 2022-2025 | Zoryve |
| Vivus LLC | $93.83 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $85.44 | 2022 | |
| Currax Pharmaceuticals LLC | $82.84 | 2023-2024 | Contrave, Onzetra Xsail |
| Sanofi Pasteur INC. | $79.82 | 2019-2023 | |
| Esperion Therapeutics, INC. | $74.32 | 2020-2024 | Nexletol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $63.13 | 2022-2025 | Xifaxan |
| Alkermes, INC. | $62.23 | 2020-2023 | Vivitrol |
| Alexion Pharmaceuticals, INC. | $59.05 | 2020-2022 | |
| Idorsia Pharmaceuticals US INC | $55.58 | 2023-2024 | Quviviq |
| Corcept Therapeutics | $54.74 | 2025 | Korlym |
| Ibsa Pharma INC. | $49.54 | 2020 | |
| Phathom Pharmaceuticals, INC. | $42.32 | 2024-2025 | Voquezna |
| Arbor Pharmaceuticals, INC. | $34.00 | 2019 | |
| Radius Health, INC. | $24.42 | 2020 | |
| Corium, LLC | $23.91 | 2022 | |
| Dexcom, INC. | $22.26 | 2024 | Dexcom G6 Transmitter |
| Nalpropion Pharmaceuticals LLC | $22.14 | 2019 | |
| Lundbeck LLC | $21.93 | 2021 | |
| Shire North American Group INC | $21.90 | 2019 | |
| Daiichi Sankyo INC. | $21.81 | 2021 | |
| Bavarian Nordic A/S | $21.79 | 2025 | Vaxchora, Vivotif |
| Hologic Sales and Service, LLC | $20.48 | 2019 | |
| Zyla Life Sciences, INC. | $19.64 | 2019 | |
| Eisai INC. | $19.53 | 2020 | |
| Aimmune Therapeutics, INC. | $19.47 | 2024 | |
| Hikma Pharmaceuticals USA | $18.92 | 2022 | |
| Seqirus USA INC | $18.87 | 2024 | Flucelvax, Fluad |
| Scilex Pharmaceuticals INC. | $18.73 | 2023 | Ztlido |
| Upsher-Smith Laboratories LLC | $16.97 | 2021 | |
| Promius Pharma LLC | $15.62 | 2019 | |
| Baxter Healthcare | $14.66 | 2025 | Hillrom - Monarch Airway Clearance System |
| Bausch Health US, LLC | $12.36 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Severance listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.